Abbott raises 2026 profit forecast on heart device strength
Abbott raises 2026 profit forecast on heart device strength July 16 (Reuters) - Abbott ABT.N raised its annual profit forecast on Thursday, as it expects strong demand for its heart devices in the second half of the year.
The company expects an adjusted profit in the range of $5.45 to $5.60 per share for 2026, compared with its previous forecast between $5.38 and $5.58 per share.
Analysts on average were expecting its annual profit to be $5.49 per share, according to data compiled by LSEG.
Investor confidence in medical device makers has climbed in recent quarters, underpinned by steady demand for heart and diabetes devices.
The company continues to expect sales growth to be between 6.5% and 7.5% for the year.
The medical device maker reported quarterly adjusted profit per share of $1.31, beating analysts' estimate of $1.28.
Total revenue came in at $12.6 billion for the second quarter, compared with expectations of $12.5 billion.
(Reporting by Siddhi Mahatole and Christy Santhosh in Bengaluru; Editing by Maju Samuel)
Recent news on Edwards Lifesciences
See all newsFDA flags Edwards heart-valve delivery system issue after death, injury (updated)
FDA flags Edwards heart-valve delivery system issue after death, injury
Brief: FDA Aware Edwards Lifesciences Issued Letter Recommending Some Delivery Systems Used For Sapien M3 Transcatheter Mitral Valve Replacement Be Removed
Brief: Edwards Lifesciences Corporation - Maintains Confidence In Financial Guidance For 2026
U.S. RESEARCH ROUNDUP-Deckers Brands, Rollins, United Rentals